




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

21460P

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/564,030	Annette S. Kim	21460P

210  
MERCK AND CO., INC  
P O BOX 2000  
RAHWAY, NJ 07065-0907



INTERNATIONAL APPLICATION NO.	
PCT/US04/23425	
I.A. FILING DATE	PRIORITY DATE
07/20/2004	07/24/2003

CONFIRMATION NO. 7209

371 FORMALITIES LETTER



\*OC000000019117188\*

*Sequence  
Requirement Due  
By 8-6-06*

Date Mailed: 06/06/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/564,030	PCT/US04/23425	21460P

FORM PCT/DO/EO/922 (371 Formalities Notice)



*Handwritten initials: J & T*

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Annette S. Kim

Serial No.: 10/564,030

Case No.: 21460P

Filed: January 9, 2006

For: TYROSINE KINASE INHIBITORS

Art Unit:

To be determined

Examiner:

To be determined

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTIFICATION TO COMPLY  
WITH SEQUENCE DISCLOSURES AND AMENDMENT**

Sir:

The amendment to the specification set out below and the submission of the computer readable copy and paper copy of the Sequence Listing are in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 6, 2006. Applicants hereby submit a paper and computer readable copy of the sequence listing.

Applicants have also submitted a statement that the contents of the sequence listing information recorded in computer readable form is identical to the written sequence and include no new matter.

Please amend the specification as described below:

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC

MAILED BY Barbara Muller DATE 7-27-06


**In the Specification:**

Insert the phrase “(SEQ.ID.NO. 1)” after the term “NH<sub>2</sub>” on page 50, line 24.

Claims 1-19 are currently pending in the instant application. Applicants are submitting a Sequence Listing (both paper and computer readable form) and have amended the specification to identify the sequences listed with the Sequence Listing ID number. Specifically, Applicants have amended the specification to include (SEQ ID No. 1) after the sequence listing on page 50, line 24. Applicants respectfully assert that no new matter has been added.

If a telephonic communication will advance the prosecution of the instant application, please contact Applicants' representative indicated below. Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees required in connection with this amendment to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By:   
Dianne Brown  
Registration No. 42,068  
Attorney for Applicant(s)

MERCK & CO., INC.  
P.O. Box 2000 – RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-1249

Date: July 27, 2006

Attachments: (1) Copy of Notice  
(2) Computer Readable Diskette  
(3) Statement